iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Glenmark Life Sciences Q4 PAT down 5.52% amid high input cost inflation

21 Apr 2022 , 12:23 AM

glenmark pharma
Glenmark Life Sciences Ltd reported 10.04% growth yoy in total revenues for the Mar-22 quarter on consolidated basis at Rs514.06cr. On a sequential basis, the revenues were lower for the quarter by -1.62%.

For FY22, revenues from the generic API segment increased by 12.1% while the CDMO business saw revenues grow by 12.4%. While regulated market revenues grew 21.4%, the emerging market revenues fell by -6.3%.

The board has recommended a final dividend of Rs.10.50/share, taking the total dividend to Rs.21.

The consolidated net profit for Q4 was down -5.52% to Rs98.90cr, while the profits were lower by -4.64% on a sequential basis.

While input costs were an issue, the emerging markets business also took a dip on profits. EBITDA margins at 28.7% in Q4 were up 10 bps on a yoy basis but 770 bps lower on a sequential basis.

Ratio of regulated to emerging markets is 72:28. Net margins for stood at 19.24% in Mar-22 quarter compared to 22.41% in Mar-21. The net profit margins were also lower by 611 basis points on a sequential basis.

Financial highlights for Mar-22 compared yoy and sequentially

Glenmark Life Sciences
Rs in Crore Mar-22 Mar-21 YOY Dec-21 QOQ
Total Income (Rs cr) ₹ 514.06 ₹ 467.16 10.04% ₹ 522.50 -1.62%
Net Profit (Rs cr) ₹ 98.90 ₹ 104.68 -5.52% ₹ 103.71 -4.64%
Diluted EPS (Rs) ₹ 8.07 ₹ 9.71 ₹ 8.65
Net Margins 19.24% 22.41% 19.85%

 

Related Tags

  • Glenmark Life Sciences management
  • Glenmark Life Sciences news
  • Glenmark Life Sciences Q4
  • Glenmark Life Sciences Q4FY22 PAT
  • Glenmark Life Sciences Q4FY22 Pharma business
  • Glenmark Life Sciences Q4FY22 Result
  • Glenmark Life Sciences quarterly results
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.